Next-generation EGFR tyrosine kinase inhibitors to overcome C797S mutation in non-small cell lung cancer (2019–2024)
RSC Medicinal Chemistry · 2024 · 15 (10) · 3371-3394
DOI: 10.1039/d4md00384e ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift RSC Medicinal Chemistry, 2024. Verfasst von Debasis Das und 2 weiteren Autor:innen. Beteiligte Einrichtung: Discovery Chemistry Research, Arromax Pharmatech Co. Ltd., Sangtiandao Science Innovation Park No. 1 Huayun Road, SIP Suzhou 215123 P. R. China debas…. Die Arbeit wurde bisher 53-mal zitiert (Crossref) und nennt 114 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar.
Abstract (Originalsprache)
Prospects of novel fourth-generation EGFR-TKIs overcoming C797S-mediated resistance in non-small cell lung cancer.
Autor:innen und Institutionen
- Discovery Chemistry Research, Arromax Pharmatech Co. Ltd., Sangtiandao Science Innovation Park No. 1 Huayun Road, SIP Suzhou 215123 P. R. China debasis.das@arromax.com.
ORCID-Profile: Debasis Das
Zitieren
APA
Das, D., Xie, L., & Hong, J. (2024). Next-generation EGFR tyrosine kinase inhibitors to overcome C797S mutation in non-small cell lung cancer (2019–2024). RSC Medicinal Chemistry, 15(10), 3371-3394. https://doi.org/10.1039/d4md00384e
Vancouver
Das D, Xie L, Hong J. Next-generation EGFR tyrosine kinase inhibitors to overcome C797S mutation in non-small cell lung cancer (2019–2024). RSC Medicinal Chemistry. 2024;15(10):3371-3394. doi:10.1039/d4md00384e
BibTeX
@article{Das2024,
author = {Das, Debasis and Xie, Lingzhi and Hong, Jian},
title = {Next-generation EGFR tyrosine kinase inhibitors to overcome C797S mutation in non-small cell lung cancer (2019–2024)},
journal = {RSC Medicinal Chemistry},
year = {2024},
volume = {15},
number = {10},
pages = {3371--3394},
doi = {10.1039/d4md00384e}
}
EUVIMED